<DOC>
	<DOCNO>NCT02980653</DOCNO>
	<brief_summary>Primary Objective : To evaluate population prevalence critical body weight loss ( 5 % baseline ) patient Head Neck cancer . Secondary Objectives : To evaluate impact appetite , performance status ; To evaluate change quality life ( QoL ) ; To evaluate incidence infection hospitalization ; To evaluate safety profile</brief_summary>
	<brief_title>Megestrol Acetate Against Cancer-related Critical Body Weight Loss Patients With H &amp; N Cancer Who Receiving CCRT</brief_title>
	<detailed_description>Hypothesis test use determine patient number study . According preliminary data CGMH-LK , investigator untreated patient population prevalence critical weight loss 0.56 , investigator assume study treat population prevalence 0.4 , power set 0.9 , alpha set 0.05 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Patient confirm diagnosis head neck cancer receive concurrent chemoradiotherapy ( CCRT ) . Patient capable understand complete questionnaires Patient convenient receive body weight measurement Life expectancy least 12 week Age 20 year old registration Voluntarily sign write informed consent form Special population need unique risk/benefit consideration . ( Ex . Pregnant nursing woman mental disorder patient , et al . ) Any significant comorbid medical condition medication control . ( Ex . Heart/renal/hepatic failure poorly control diabetes , et al . ) Any evidence mechanical obstruction alimentary track , malabsorption , intractable vomit . Any thromboembolism event , e.g . cerebral peripheral vascular disease Judged ineligible physician participation study due safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Phase II study</keyword>
	<keyword>Critical body weight loss</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Megestrol acetate</keyword>
	<keyword>Head neck cancer</keyword>
</DOC>